Lucid Diagnostics Inc

$3.86 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Lucid Diagnostics Inc

ucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The company is a subsidiary of PAVmed Inc.

Stock Analysis

last close $3.86
1-mo return -22.3%
3-mo return -59.5%
avg daily vol. 346.47T
52-week high 13.52
52-week low 3.75
market cap. $157M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 4.4%

Subscribe now for daily local and international financial news